Detection of soluble EpCAM in malignant ascites to predict overall survival in patients treated with catumaxomab

Autor:	Alain G. Zeimet, Dominic Fong, Laura Botta, Gilbert Spizzo, Heidi Fiegl, Agnieszka Martowicz, Mani Nassir, Ioana Braicu, Andreas Seeber, Jalid Sehouli, Normann Steiner, Gerold Untergasser, Guenther Gastl
Rok vydání:	2014
Předmět:	Cancer Research medicine.medical_specialty Pathology biology business.industry Catumaxomab Gastroenterology Intraperitoneal treatment Oncology Internal medicine Ascites medicine Overall survival biology.protein In patient medicine.symptom Antibody business medicine.drug
Zdroj:	Journal of Clinical Oncology. 32:e15173-e15173
ISSN:	1527-7755 0732-183X
Popis:	e15173 Background: The EpCAM-specific antibody catumaxomab has been approved for intraperitoneal treatment of patients suffering from malignant ascites. New prognostic markers are necessary to sele...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::fd1eeb291566cd88fa1e227fed50c2be https://doi.org/10.1200/jco.2014.32.15_suppl.e15173 Zobrazit plný text záznamu